News Focus
News Focus
Post# of 257575
Next 10
Followers 843
Posts 122986
Boards Moderated 9
Alias Born 09/05/2002

Re: biocqr post# 188177

Tuesday, 06/20/2017 9:14:11 AM

Tuesday, June 20, 2017 9:14:11 AM

Post# of 257575
(REGN)—NVS’ RTH258 non-inferior to Eylea with less-frequent injections:

https://www.novartis.com/news/media-releases/novartis-rth258-brolucizumab-demonstrates-robust-visual-gains-namd-patients

Detailed data at an upcoming medical conference.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up